Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

BMC Endocrine Disorders

Table 9 Laboratory adverse experience summary

	Sitagliptin 100 mg n (%) (N = 3375)	Non-Exposed n (%) (N = 2680)	Difference in Sitagliptin and Non-Exposed % (95% CI)*
With one or more adverse experiences	378 (11.2)	293 (10.9)	0.3 (-1.3, 1.8)
With drug-related adverse experiences^†	102 (3.0)	78 (2.9)	0.1 (-0.8, 1.0)
With serious adverse experiences	3 (0.1)	0 (0)	0.1 (-0.1, 0.3)
With serious drug-related adverse experiences^†	0 (0)	0 (0)	0.0 (-0.1, 0.1)
Who died	0 (0)	0 (0)	0.0 (-0.1, 0.1)
Discontinued due to adverse experiences	36 (1.1)	18 (0.7)	0.4 (-0.1, 0.9)
Discontinued due to drug-related adverse experiences	16 (0.5)	9 (0.3)	0.1 (-0.2, 0.5)
Discontinued due to serious adverse experiences	0 (0)	0 (0)	0.0 (-0.1, 0.1)
Discontinued due to serious drug-related adverse experiences	0 (0)	0 (0)	0.0 (-0.1, 0.1)

CI = confidence interval
*Positive differences indicate that the incidence rate for the sitagliptin group is higher than the incidence rate for the non-exposed group. "0.0" and "-0.0" represent rounding for values that are slightly greater and slightly less than zero, respectively.
^†Determined by the investigator to be possibly, probably, or definitely drug-related.

ISSN: 1472-6823